The findings of this study demonstrate that low B3GNT6 expression is a potential biomarker of poor outcomes in patients with CRC and may lead to more frequent activation of the KRAS/ERK signaling pathway, CIN, and increased proteasomal activity. The gene discussed is B3GNT6; the disease is colorectal carcinoma.